Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
NeuroVive Pharmaceutical AB Interim Report January - March 2019 First subjects enrolled in the KL1333 study PR Newswire STOCKHOLM, May 21, 2019...
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA PR Newswire LUND, Sweden, May 10, 2019 LUND, Sweden, May 10, 2019...
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report PR Newswire LUND, Sweden, 25 March 2019 LUND, Sweden, 25 March 2019 /PRNewswire/...
NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue PR Newswire LUND, Sweden, March 7, 2019 LUND, Sweden, March 7, 2019...
NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds PR Newswire LUND, Sweden, Feb. 21...
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders PR Newswire LUND...
NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1 PR Newswire LUND, Sweden...
NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI PR Newswire LUND, Sweden, Oct. 4, 2018 LUND, Sweden, Oct. 4, 2018 /PRNewswire/...
NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI PR Newswire LUND, Sweden, Oct. 4, 2018 LUND, Sweden, Oct. 4, 2018 NeuroVive...
NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333 PR Newswire LUND, Sweden, Dec. 11, 2017...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지